Chung Chun Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chung Chun Lee has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Jong-Yeup Kim
Department of Biomedical Informatics, Konyang University College of Medicine, Daejeon, Korea
4 shared publications - Suehyun Lee
Department of Computer Engineering, College of IT Convergence, Gachon University, Seongnam, Republic of Korea
4 shared publications - Ju Han Kim
Seoul National University Biomedical Informatics (SNUBI), Division of Biomedical Informatics, Seoul National University College of Medicine, Seoul, Korea
3 shared publications - Grace Juyun Kim
Big Data Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea
2 shared publications - Jee-Young Hong
Department of Preventive Medicine, College of Medicine, Jeonbuk National University, Jeonju, Korea
2 shared publications - Kwangsoo Kim
Department of Transdisciplinary Medicine Seoul National University Hospital Seoul Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 6 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Development of a Common Data Model for Active Medical Device Safety Surveillance using Real-World Data (Preprint)
BACKGROUND Adverse events (AEs) are frequently associated with the use of medical devices, yet effective post-market surveillance remains limited because device usage is rarely captured in a structured form and voluntary reporting is incomplete. Common data model (CDM)-based distributed research networks allow clinical evidence to be shared across institutions without transferring patient-level data, but existing CDMs contain little of the device-specific information required for medical device vigilance. OBJECTIVE We aimed to develop a Korean Common Data Model for Medical Device Vigilance (K-CDM MDV) that supports structured, real-world data (RWD)-driven active surveillance of device-related AEs, and to evaluate its feasibility using electronic medical record (EMR) data from a single tertiary hospital. METHODS The K-CDM MDV was designed from voluntary Medical Device Reports (MDRs) of several countries and from device- and AE-related elements of the Observational Medical Outcomes Partnership (OMOP), Sentinel, and PCORnet CDMs, and extended with standardized device usage data and Unique Device Identifiers (UDIs) to interoperate with existing CDMs. As a pilot application, EMR records of patients who used a hemodialysis machine or a coronary stent at Konyang University Hospital (KYUH) between 2012 and 2019 were pseudonymized, transformed, and loaded into the K-CDM MDV. Two scenario-based hypotheses were examined: the time-dependent risk of hypotension for two hemodialysis machines, and the severity of AEs across coronary stent types. Descriptive analyses, t tests, relative risks, odds ratios, survival analysis, and analysis of variance were performed in R (version 4.1.0); statistical significance was set at p < 0.05. RESULTS The K-CDM MDV consists of five tables (DEVICE_EXPOSURE, DEVICE_AE, DEVICE_AE_INVOLVED, DEFECTIVE_MD, and META_DEVICE) and connects to external standard CDMs through the DEVICE_EXPOSURE table. In total, 8,064 hemodialysis machine use records and 3,156 coronary stent implantation records were transformed into the model. AEs were reported in 161 of 4,832 uses (3.3%) for device A and in 87 of 3,241 uses (2.7%) for device B; the survival probability of device A decreased to approximately 0.97 after two hours of hemodialysis, whereas that of device B remained near 1.00 until four hours. For coronary stents, information on thrombosis could not be obtained from the existing coded data, and crude AE incidence by stent type ranged from 0.4% to 14.3%. The comparison of AE severity across stent types was not statistically significant (p = 0.4405; F = 1.003), with a small effect size (eta-squared = 0.037). CONCLUSIONS The K-CDM MDV offers a standardized and interoperable structure that captures both detailed device usage and the causes of AEs. Although it was developed and evaluated in a single-institution setting, its design supports integration across multiple institutions and provides a scalable foundation for national-level active medical device surveillance and for informed policy development.
- 6 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDevelopment of a Common Data Model for Active Medical Device Safety Surveillance using Real-World Data (Preprint)
BACKGROUND Adverse events (AEs) are frequently associated with the use of medical devices, yet effective post-market surveillance remains limited because device usage is rarely captured in a structured form and voluntary reporting is incomplete. Common data model (CDM)-based distributed research networks allow clinical evidence to be shared across institutions without transferring patient-level data, but existing CDMs contain little of the device-specific information required for medical device vigilance. OBJECTIVE We aimed to develop a Korean Common Data Model for Medical Device Vigilance (K-CDM MDV) that supports structured, real-world data (RWD)-driven active surveillance of device-related AEs, and to evaluate its feasibility using electronic medical record (EMR) data from a single tertiary hospital. METHODS The K-CDM MDV was designed from voluntary Medical Device Reports (MDRs) of several countries and from device- and AE-related elements of the Observational Medical Outcomes Partnership (OMOP), Sentinel, and PCORnet CDMs, and extended with standardized device usage data and Unique Device Identifiers (UDIs) to interoperate with existing CDMs. As a pilot application, EMR records of patients who used a hemodialysis machine or a coronary stent at Konyang University Hospital (KYUH) between 2012 and 2019 were pseudonymized, transformed, and loaded into the K-CDM MDV. Two scenario-based hypotheses were examined: the time-dependent risk of hypotension for two hemodialysis machines, and the severity of AEs across coronary stent types. Descriptive analyses, t tests, relative risks, odds ratios, survival analysis, and analysis of variance were performed in R (version 4.1.0); statistical significance was set at p < 0.05. RESULTS The K-CDM MDV consists of five tables (DEVICE_EXPOSURE, DEVICE_AE, DEVICE_AE_INVOLVED, DEFECTIVE_MD, and META_DEVICE) and connects to external standard CDMs through the DEVICE_EXPOSURE table. In total, 8,064 hemodialysis machine use records and 3,156 coronary stent implantation records were transformed into the model. AEs were reported in 161 of 4,832 uses (3.3%) for device A and in 87 of 3,241 uses (2.7%) for device B; the survival probability of device A decreased to approximately 0.97 after two hours of hemodialysis, whereas that of device B remained near 1.00 until four hours. For coronary stents, information on thrombosis could not be obtained from the existing coded data, and crude AE incidence by stent type ranged from 0.4% to 14.3%. The comparison of AE severity across stent types was not statistically significant (p = 0.4405; F = 1.003), with a small effect size (eta-squared = 0.037). CONCLUSIONS The K-CDM MDV offers a standardized and interoperable structure that captures both detailed device usage and the causes of AEs. Although it was developed and evaluated in a single-institution setting, its design supports integration across multiple institutions and provides a scalable foundation for national-level active medical device surveillance and for informed policy development.
- Open Access
- 1 June 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e78353
Multi-institutional drug use patterns in hospitalized elderly patients: a retrospective cross sectional study (Preprint)
A rapidly aging population led to an increase in the number of patients with chronic diseases and polypharmacy. Although investigations on the appropriate number of drugs for older patients have been conducted, there is a shortage of studies on polypharmacy criteria in older inpatients from multiple institutions. The aim of this study was to examine the patterns of polypharmacy and determine the criteria for the number of drugs defining polypharmacy in the geriatric inpatient population. Electronic health records of 4 medical institutions for patients aged 65 years and older hospitalized between January 1, 2012, and December 31, 2020, were analyzed for the study. The maximum number of drugs prescribed was obtained for each patient and, along with a literature review, was used to determine the appropriate polypharmacy level for our population. We suggest a 4-level polypharmacy category system consisting of nonpolypharmacy, polypharmacy, major polypharmacy, and excessive polypharmacy based on a review of international guidelines and polypharmacy literature. Application of this system to our study population showed that the major polypharmacy category (use of 10-19 concurrent drugs) was an appropriate threshold for polypharmacy in hospitalized patients versus the traditional threshold of 5 or more concurrent drugs. The tendency of our study population to have a higher disease and drug count supports this threshold. Frequently prescribed therapeutic subgroups in this category were antibacterials for systemic use, anesthetics, and cardiac therapy. This study proposes a polypharmacy categorization system for older inpatients, which differs from the common definition of the concomitant prescription of 5 or more drugs. The older population tends to have severe conditions including those requiring major surgeries; therefore, a drug count corresponding to the definition of major polypharmacy is appropriate.
- 1 June 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e78353
Open AccessMulti-institutional drug use patterns in hospitalized elderly patients: a retrospective cross sectional study (Preprint)
A rapidly aging population led to an increase in the number of patients with chronic diseases and polypharmacy. Although investigations on the appropriate number of drugs for older patients have been conducted, there is a shortage of studies on polypharmacy criteria in older inpatients from multiple institutions. The aim of this study was to examine the patterns of polypharmacy and determine the criteria for the number of drugs defining polypharmacy in the geriatric inpatient population. Electronic health records of 4 medical institutions for patients aged 65 years and older hospitalized between January 1, 2012, and December 31, 2020, were analyzed for the study. The maximum number of drugs prescribed was obtained for each patient and, along with a literature review, was used to determine the appropriate polypharmacy level for our population. We suggest a 4-level polypharmacy category system consisting of nonpolypharmacy, polypharmacy, major polypharmacy, and excessive polypharmacy based on a review of international guidelines and polypharmacy literature. Application of this system to our study population showed that the major polypharmacy category (use of 10-19 concurrent drugs) was an appropriate threshold for polypharmacy in hospitalized patients versus the traditional threshold of 5 or more concurrent drugs. The tendency of our study population to have a higher disease and drug count supports this threshold. Frequently prescribed therapeutic subgroups in this category were antibacterials for systemic use, anesthetics, and cardiac therapy. This study proposes a polypharmacy categorization system for older inpatients, which differs from the common definition of the concomitant prescription of 5 or more drugs. The older population tends to have severe conditions including those requiring major surgeries; therefore, a drug count corresponding to the definition of major polypharmacy is appropriate.
- Open Access
- 1 June 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Multi-Institutional Drug Use Patterns in Hospitalized Older Patients: Retrospective Cross-Sectional Study (Preprint)
BACKGROUND A rapidly aging population led to an increase in the number of patients with chronic diseases and polypharmacy. Although investigations on the appropriate number of drugs for older patients have been conducted, there is a shortage of studies on polypharmacy criteria in older inpatients from multiple institutions. OBJECTIVE The aim of this study was to examine the patterns of polypharmacy and determine the criteria for the number of drugs defining polypharmacy in the geriatric inpatient population. METHODS Electronic health records of 4 medical institutions for patients aged 65 years and older hospitalized between January 1, 2012, and December 31, 2020, were analyzed for the study. The maximum number of drugs prescribed was obtained for each patient and, along with a literature review, was used to determine the appropriate polypharmacy level for our population. RESULTS We suggest a 4-level polypharmacy category system consisting of nonpolypharmacy, polypharmacy, major polypharmacy, and excessive polypharmacy based on a review of international guidelines and polypharmacy literature. Application of this system to our study population showed that the major polypharmacy category (use of 10-19 concurrent drugs) was an appropriate threshold for polypharmacy in hospitalized patients versus the traditional threshold of 5 or more concurrent drugs. The tendency of our study population to have a higher disease and drug count supports this threshold. Frequently prescribed therapeutic subgroups in this category were antibacterials for systemic use, anesthetics, and cardiac therapy. CONCLUSIONS This study proposes a polypharmacy categorization system for older inpatients, which differs from the common definition of the concomitant prescription of 5 or more drugs. The older population tends to have severe conditions including those requiring major surgeries; therefore, a drug count corresponding to the definition of major polypharmacy is appropriate.
- 1 June 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessMulti-Institutional Drug Use Patterns in Hospitalized Older Patients: Retrospective Cross-Sectional Study (Preprint)
BACKGROUND A rapidly aging population led to an increase in the number of patients with chronic diseases and polypharmacy. Although investigations on the appropriate number of drugs for older patients have been conducted, there is a shortage of studies on polypharmacy criteria in older inpatients from multiple institutions. OBJECTIVE The aim of this study was to examine the patterns of polypharmacy and determine the criteria for the number of drugs defining polypharmacy in the geriatric inpatient population. METHODS Electronic health records of 4 medical institutions for patients aged 65 years and older hospitalized between January 1, 2012, and December 31, 2020, were analyzed for the study. The maximum number of drugs prescribed was obtained for each patient and, along with a literature review, was used to determine the appropriate polypharmacy level for our population. RESULTS We suggest a 4-level polypharmacy category system consisting of nonpolypharmacy, polypharmacy, major polypharmacy, and excessive polypharmacy based on a review of international guidelines and polypharmacy literature. Application of this system to our study population showed that the major polypharmacy category (use of 10-19 concurrent drugs) was an appropriate threshold for polypharmacy in hospitalized patients versus the traditional threshold of 5 or more concurrent drugs. The tendency of our study population to have a higher disease and drug count supports this threshold. Frequently prescribed therapeutic subgroups in this category were antibacterials for systemic use, anesthetics, and cardiac therapy. CONCLUSIONS This study proposes a polypharmacy categorization system for older inpatients, which differs from the common definition of the concomitant prescription of 5 or more drugs. The older population tends to have severe conditions including those requiring major surgeries; therefore, a drug count corresponding to the definition of major polypharmacy is appropriate.
- Open Access
- 20 November 2024
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 12, e45289
Bidirectional Long Short-Term Memory–Based Detection of Adverse Drug Reaction Posts Using Korean Social Networking Services Data: Deep Learning Approaches
Background: Social networking services (SNS) closely reflect the lives of individuals in modern society and generate large amounts of data. Previous studies have extracted drug information using relevant SNS data. In particular, it is important to detect adverse drug reactions (ADRs) early using drug surveillance systems. To this end, various deep learning methods have been used to analyze data in multiple languages in addition to English. Objective: A cautionary drug that can cause ADRs in older patients was selected, and Korean SNS data containing this drug information were collected. Based on this information, we aimed to develop a deep learning model that classifies drug ADR posts based on a recurrent neural network. Methods: In previous studies, ketoprofen, which has a high prescription frequency and, thus, was referred to the most in posts secured from SNS data, was selected as the target drug. Blog posts, café posts, and NAVER Q&A posts from 2005 to 2020 were collected from NAVER, a portal site containing drug-related information, and natural language processing techniques were applied to analyze data written in Korean. Posts containing highly relevant drug names and ADR word pairs were filtered through association analysis, and training data were generated through manual labeling tasks. Using the training data, an embedded layer of word2vec was formed, and a Bidirectional Long Short-Term Memory (Bi-LSTM) classification model was generated. Then, we evaluated the area under the curve with other machine learning models. In addition, the entire process was further verified using the nonsteroidal anti-inflammatory drug aceclofenac. Results: Among the nonsteroidal anti-inflammatory drugs, Korean SNS posts containing information on ketoprofen and aceclofenac were secured, and the generic name lexicon, ADR lexicon, and Korean stop word lexicon were generated. In addition, to improve the accuracy of the classification model, an embedding layer was created considering the association between the drug name and the ADR word. In the ADR post classification test, ketoprofen and aceclofenac achieved 85% and 80% accuracy, respectively. Conclusions: Here, we propose a process for developing a model for classifying ADR posts using SNS data. After analyzing drug name-ADR patterns, we filtered high-quality data by extracting posts, including known ADR words based on the analysis. Based on these data, we developed a model that classifies ADR posts. This confirmed that a model that can leverage social data to monitor ADRs automatically is feasible.
- 20 November 2024
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 12, e45289
Open AccessBidirectional Long Short-Term Memory–Based Detection of Adverse Drug Reaction Posts Using Korean Social Networking Services Data: Deep Learning Approaches
Background: Social networking services (SNS) closely reflect the lives of individuals in modern society and generate large amounts of data. Previous studies have extracted drug information using relevant SNS data. In particular, it is important to detect adverse drug reactions (ADRs) early using drug surveillance systems. To this end, various deep learning methods have been used to analyze data in multiple languages in addition to English. Objective: A cautionary drug that can cause ADRs in older patients was selected, and Korean SNS data containing this drug information were collected. Based on this information, we aimed to develop a deep learning model that classifies drug ADR posts based on a recurrent neural network. Methods: In previous studies, ketoprofen, which has a high prescription frequency and, thus, was referred to the most in posts secured from SNS data, was selected as the target drug. Blog posts, café posts, and NAVER Q&A posts from 2005 to 2020 were collected from NAVER, a portal site containing drug-related information, and natural language processing techniques were applied to analyze data written in Korean. Posts containing highly relevant drug names and ADR word pairs were filtered through association analysis, and training data were generated through manual labeling tasks. Using the training data, an embedded layer of word2vec was formed, and a Bidirectional Long Short-Term Memory (Bi-LSTM) classification model was generated. Then, we evaluated the area under the curve with other machine learning models. In addition, the entire process was further verified using the nonsteroidal anti-inflammatory drug aceclofenac. Results: Among the nonsteroidal anti-inflammatory drugs, Korean SNS posts containing information on ketoprofen and aceclofenac were secured, and the generic name lexicon, ADR lexicon, and Korean stop word lexicon were generated. In addition, to improve the accuracy of the classification model, an embedding layer was created considering the association between the drug name and the ADR word. In the ADR post classification test, ketoprofen and aceclofenac achieved 85% and 80% accuracy, respectively. Conclusions: Here, we propose a process for developing a model for classifying ADR posts using SNS data. After analyzing drug name-ADR patterns, we filtered high-quality data by extracting posts, including known ADR words based on the analysis. Based on these data, we developed a model that classifies ADR posts. This confirmed that a model that can leverage social data to monitor ADRs automatically is feasible.
- Open Access
- 1 February 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Detection of novel drug-adverse drug reaction signals in rheumatoid arthritis and ankylosing spondylitis: analysis of Korean real-world biologics registry data
This study aimed to detect signals of adverse drug reactions (ADRs) associated with biological disease-modifying antirheumatic drugs (DMARDs) and targeted therapies in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients. Utilizing the KOrean College of Rheumatology BIOlogics & Targeted Therapy Registry (KOBIO) data, we calculated relative risks, excluded previously reported drug-ADR pairs, and externally validated remaining pairs using US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and single centre’s electronic health records (EHR) data. Analyzing data from 2279 RA and 1940 AS patients, we identified 35 significant drug-ADR pairs in RA and 26 in AS, previously unreported in drug labels. Among the novel drug-ADR pairs from KOBIO, 15 were also significant in the FAERS data. Additionally, 2 significant drug-laboratory abnormality pairs were found in RA using CDM MetaLAB analysis. Our findings contribute to the identification of 14 novel drug-ADR signals, expanding our understanding of potential adverse effects related to biological DMARDs and targeted therapies in RA and AS. These results emphasize the importance of ongoing pharmacovigilance for patient safety and optimal therapeutic interventions.
- 1 February 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Open AccessDetection of novel drug-adverse drug reaction signals in rheumatoid arthritis and ankylosing spondylitis: analysis of Korean real-world biologics registry data
This study aimed to detect signals of adverse drug reactions (ADRs) associated with biological disease-modifying antirheumatic drugs (DMARDs) and targeted therapies in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients. Utilizing the KOrean College of Rheumatology BIOlogics & Targeted Therapy Registry (KOBIO) data, we calculated relative risks, excluded previously reported drug-ADR pairs, and externally validated remaining pairs using US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and single centre’s electronic health records (EHR) data. Analyzing data from 2279 RA and 1940 AS patients, we identified 35 significant drug-ADR pairs in RA and 26 in AS, previously unreported in drug labels. Among the novel drug-ADR pairs from KOBIO, 15 were also significant in the FAERS data. Additionally, 2 significant drug-laboratory abnormality pairs were found in RA using CDM MetaLAB analysis. Our findings contribute to the identification of 14 novel drug-ADR signals, expanding our understanding of potential adverse effects related to biological DMARDs and targeted therapies in RA and AS. These results emphasize the importance of ongoing pharmacovigilance for patient safety and optimal therapeutic interventions.